Absci Corp (ABSI)vsAstraZeneca PLC (AZN)
ABSI
Absci Corp
$7.51
-7.97%
HEALTHCARE · Cap: $1.74B
AZN
AstraZeneca PLC
$174.35
-0.60%
HEALTHCARE · Cap: $293.73B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3996313% more annual revenue ($62.38B vs $1.56M). AZN leads profitability with a 17.7% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 68/100 (B-).
ABSI
Avoid20
out of 100
Grade: F
AZN
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.6%
Fair Value
$1.57
Current Price
$7.51
$5.94 premium
Margin of Safety
+11.8%
Fair Value
$197.76
Current Price
$174.35
$23.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABSI
The strongest argument for ABSI centers on Debt/Equity.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bear Case : ABSI
The primary concerns for ABSI are EPS Growth, Market Cap, Profit Margin.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ABSI profiles as a value stock while AZN is a mature play — different risk/reward profiles.
ABSI carries more volatility with a beta of 2.19 — expect wider price swings.
AZN is growing revenue faster at 6.7% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (68/100 vs 20/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Absci Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci effectively shortens development timelines and lowers associated costs, establishing itself as a key innovator within the biopharmaceutical sector. The company's robust pipeline, complemented by strategic partnerships, underscores its commitment to advancing next-generation therapies that address critical medical needs and improve patient outcomes.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?